BioMap entered a strategic collaboration with Sanofi to co-develop AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. BioMap will receive an upfront payment and near-term payments for reaching module development milestones. BioMap is eligible to receive payments of more than $1 billion based on achievement of preclinical development, clinical development, regulatory, and commercial milestones.
 
Leveraging BioMap’s custom-built foundational models and AI expertise, as well as Sanofi’s proprietary data, computational innovations in protein engineering, and biologics development experience, both parties aim to create advanced AI models and protein Large Language Models that will enable biologics design and multiparametric optimization.
 
“As the largest foundational model-based approach within life sciences, we are thrilled to collaborate with Sanofi and leverage the potential of BioMap’s cutting-edge AI engine to help solve complex problems associated with new protein therapies to drive drug discovery,” said BioMap’s Chief Technology Officer, Le Song. “We have built what is essentially a biological map of proteins using data sets from public and private sources to inform our foundational models. Utilizing automation and integrated workflows to enhance the collection of high-quality data, we can catalyze the process of new hit discovery and lead optimization.”
 
“By combining Sanofi’s proprietary data sets, digital infrastructure, AI and data science capabilities, and drug development expertise with BioMap’s protein Large Language Models, high-performance computing, and deep understanding of AI, we can optimize the process of discovery and development of breakthrough biotherapeutics,” said Matt Truppo, Global Head of Research Platforms at Sanofi. “Our collaboration with BioMap further underscores Sanofi’s commitment to becoming the first pharma company powered by artificial intelligence at scale.”